On January 12, 2021 Dragonfly Therapeutics ("Dragonfly"), a biotechnology company developing new immunotherapies that harness the innate immune system to treat disease, reported that AbbVie (NYSE: ABBV ) has licensed its first drug candidate TriNKET from Dragonfly, part of a multi-objective collaboration started in November 2019 designed to advance a series of new immunotherapies based on Dragonfly NK cell implicators for autoimmune and oncological indications (Press release, Dragonfly Therapeutics, JAN 12, 2021, View Source;876043116.html [SID1234573935]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"AbbVie is committed to providing improved treatment options for our patients," said Tom Hudson , MD, senior vice president of R&D and chief science officer for AbbVie. "The collaboration with Dragonfly has been remarkable. Working together, the teams have made rapid progress to develop this first TriNKET in record time."
"AbbVie is a global leader in the treatment of immune diseases," said Bill Haney , co-founder and CEO of Dragonfly. "They are a terrifying partner and this membership, as soon as we launch our collaboration, is a huge vote of confidence. We look forward to continued success and rapid progress with the AbbVie team to advance new treatment options for patients."
The listing grants AbbVie exclusive global intellectual property rights to develop and commercialize products targeting this first specific goal, developed using Dragonfly’s TriNKET technology platform. Dragonfly will receive a membership payment, as well as potential future development milestone payments and royalties from the sales of marketed candidates.